Noninvasive staging of fibrosis in patients with chronic Hepatitis C: correlation of FIB-4 and APRI to Fibroscan

Background and Aims: Treatment decisions with regimens containing direct acting antivirals (DAA) highly depend on accurate fibrosis staging. Fibroscan® has become a gold standard for non-invasive staging of fibrosis; however this method is not universally available. Thus, we compared the performance of Fibroscan® to the standardly available serologic tests AST to platelet ratio (APRI) and FIB-4. Methods: A total of 440 consecutive patients [m/f: 296/144, mean age: 49 ± 14, mean BMI 26.6 ± 4.0, treatment naive/experienced 321/119, genotype (GT) 1: 282 (64.1%), GT 2: 9 (2.0%), GT 3: 86 (19.5%), GT 4: 36 (8.2%), GT…